pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CAPRCAPRICOR THERAPEUTICS, INC.

$CAPR6.6500+57.96%
San Diego, CA, USupdated 14m ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 1: 1pre_registration: 1
1Phase 11pre_registration
Phase 1
Exosome-Based Vaccine
Coronavirus Disease 2019 (COVID-19)
pre_registration
deramiocel
Cardiomyopathy

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 11, 2026
earnings
$CAPR6.6500+57.96%
3d ago
CAPRICOR THERAPEUTICS, INC. earnings
CAPRICOR THERAPEUTICS, INC.
→
view all catalysts →

Active trials

  • phase3A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophyactive not recruitingn=106
  • phase2Open-label Extension of the HOPE-2 Trialactive not recruitingn=13
  • phase2A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophycompletedn=20
  • phase2Intravenous Infusion of CAP-1002 in Patients With COVID-19completedn=55
  • phase2HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)completedn=25
  • phase2Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)completedn=8
  • phase2Allogeneic Heart Stem Cells to Achieve Myocardial Regenerationterminatedn=135

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 2, 26SELLSabar Karimah Es· 7,529 sh @ $32.00−$241K↗
  • Apr 1, 26SELLSabar Karimah Es· 53,735 sh @ $31.03−$1.67M↗
  • Mar 31, 26SELLSabar Karimah Es· 61,265 sh @ $30.17−$1.85M↗
  • Mar 31, 26SELLBergmann Anthony· CHIEF FINANCIAL OFFICER25,000 sh @ $30.13−$753K↗
  • Mar 31, 26SELLKrasney Karen· EVP, GENERAL COUNSEL25,000 sh @ $30.12−$753K↗
routine RSU / option mechanics (6)
  • Apr 2, 26option exerciseSabar Karimah Es · 7,529 sh
  • Apr 2, 26option exerciseSabar Karimah Es · 7,529 sh
  • Apr 1, 26option exerciseSabar Karimah Es · 53,735 sh
  • Apr 1, 26option exerciseSabar Karimah Es · 53,735 sh
  • Mar 31, 26option exerciseSabar Karimah Es · 61,265 sh
  • Mar 31, 26option exerciseKrasney Karen · EVP, GENERAL COUNSEL21,488 sh
🐶 Hiring Signal
32 open roles at CAPRICOR THERAPEUTICS, INC. →

Where CAPRICOR THERAPEUTICS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaRare Disease 29CNS / Neuroscience 3
departmentQuality 9Manufacturing / CMC 7Commercial 3Medical Affairs 3Supply Chain 3R&D / Discovery 1

News

  • UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
    UniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by R…
    biospace · 14d ago
  • STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
    Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
    stat · 18d ago
identifiers
ticker
$CAPR
SEC CIK
0001133869
country
US
source
sec_tickers
top tags
Cardiology1Duchenne Muscular Dystrophy1Infectious Disease1
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 16m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?